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Introduction 
Biopharmaceuticals have established themselves as highly efficient medicines, and are still one of the fastest growing parts of the 
health-product industry. Unfortunately, the introduction of these promising new drugs went hand in hand with the creation of a 
black market for falsified biotechnology drugs. Particularly popular are the lyophilised peptides with a molecular weight of less than 5 
kDa. Multiple systems based on reversed-phase LC have been developed to tackle these grievous practices.  
The emerging of more polar peptides however requires the introduction of other separation techniques such as Hydrophilic Liquid 
Interaction Chromatography (HILIC) .  
HILIC chromatography allows for the analysis of polar (or ionic) compounds based on a bifasic (aqueous/organic) system and is 
compatible with mass spectrometric detection (no ion pairing agents necessary). Therefore, we set out to develop and validate an 
analytical method based on HILIC to identify and quantify the most frequently encountered illegal peptides on the European 
market. For this objective, five HILIC columns with different types of stationary phases were tested on their 
chromatographic performance in terms of resolution and peak symmetry. The most suitable system was 
subsequently optimised and validated for the detection and quantification of these illegal preparations. 
 
 
Set-up 
Ten peptides (doping peptides, hormones, 
     preclinical drugs) 
 Five HILIC columns: 
 
 
 
 
 
 
 
 Gradient: 80% to 40% Acetonitrile 
 Gradient time: 15 min 
 Linear increase: 4% ACN/ min 
 Additive: 10 mM ammonium formate pH 3.0 
 Sample solvent: Initial conditions 
   (10 mM ammonium formate 80% ACN) 
 
Variables 
 Flow: 0.2, 0.3, 0.4, 0.5 mL/min 
 Temperature: 30, 40, 50 °C 
 
Response variables 
 Resolution 
 Peak symmetry 
 
Identification 
UHPLC-MS²: Dionex UltiMate 3000 (Thermo 
Scientific, USA) hyphenated to an AmaZon™ speed 
ETD MS (Bruker, Germany) 
 
MS-settings: ESI(+), mass range 300-1200 m/z 
 
Criteria 
 Selectivity: Matrix comprised of  150 mM  
  NaCl, 10 mM Na2PO4, 0.02% PEG, 5%  
 mannitol 
 Sensitivity: S/N ≥ 3.3 
 Peptide identification: (Cf. Sport drug testing) 
  Correct MS mass (±0.3 Da) 
  Minimum 2 MS² fragments (±1.0 Da) 
 
Acquired screening detection limit = 10 µg/mL 
 
Quantification 
Acquity UPLC coupled to a DAD detector (Waters, 
USA) 
 
Settings: detection wavelength 214 or 277 nm 
 
Validation performed according to ISO 17025 in 
matrix for 6 peptides as proof of principle 
 
 
 
 
 
Obtained result Criteria 
Limit of quantification 
(max.) 
50 or 100 µg/mL 100 µg/mL 
Validated range LOQ  to 500 µg/mL 
Relative bias (max %) + 7.58 < ± 20% 
Repeatability (max 
RSD%) 
7.66 < 15% 
Intermediate Precision 
(max RSD%) 
8.16 < 15% 
Relative expanded 
uncertainty (max %) 
17.15 < 20% 
Full chromatographic separation  
Separation of critical pare @ 
 Flow: 0.27 ml/min 
 Temperature: 45°C 
 Gradient time: 20 min (red line) 
 Linear increase gradient: 3% ACN/min 
 
Matrix effect 
Matrix constituents falsified products : 
150 mM NaCl, 10 mM Na2PO4, 1% PEG, 5% 
mannitol 
Recoveries at high concentrations  influenced  
by mannitol 
 => Solved by changing sample solvent to:  
 10 mM ammonium formate 80% ACN + 
  2%  formic acid 
 
Enhanced stability due to 
1) Introduction of  online cleaning step 
(blue line) to wash away remaining  matrix 
constituents of falsified preparations 
 
  
2) Washing column at low flow rate with 
 25 mM ammonium formate 80% H2O after 100 
injections 
Acquity BEH HILIC (100x2.1mm,1.7 µm) 
Acquity BEH HILIC amide (100x2.1mm,1.7 µm) 
Acquity Cortecs HILIC  (100x2.1mm,1.6 µm) 
Merck  ZIC HILIC  (100x2.1mm, 3.5 µm) 
Merck  ZIC-c HILIC (100x2.1mm, 3.0 µm) 
Conclusion 
In this study a ZIC HILIC system was selected in favour of four other columns based on the chromatographic performance with frequently encountered 
peptide drugs on the European market. The selected HILIC-system was further refined and validated according to the ISO 17025 guideline.  
The developed ZIC HILIC system allows for the detection and quantification of a wide spectrum of falsified peptide drugs available on the internet.  
Furthermore, the method could also be envisaged for the detection of new emerging polar peptide drugs found in cosmetics. 
 Based on Janvier et al. 2017 
HILIC Figure: http://www.sielc.com/Technology_HILIC.html 
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 Best chromatogram:  ZIC HILIC  @ 0.2 mL/min,  50°C 
Time (min) 
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